



Native Cardiovascular

Media Release

Native Cardiovascular Inc.

Corporate Office:

3384 Woods Edge Circle

Suite 102

Bonita Springs, FL 34134

Phone: (239) 597-3564

Fax: (239) 908-4435

www.NativeCVS.com

FOR IMMEDIATE RELEASE

For Further Information Call Gary Dixon

Phone: (239) 597-3564

Dr. Robert B. Raffa Joins Native Cardiovascular Scientific Advisory Board

Temple University Professor Adds Pharmacology Expertise to Board

Bonita Springs, FL, September 25, 2015/ Today, Native Cardiovascular Inc. announced that Robert B. Raffa, Ph.D. has joined its Scientific Advisory Board. Dr. Raffa is Professor of Pharmacology in the Department of Pharmaceutical Sciences at Temple University School of Pharmacy and Research Professor in the Department of Pharmacology of Temple University School of Medicine, Philadelphia, Pennsylvania.

“I am very pleased to join the Scientific Advisory Board at Native Cardiovascular,” Dr. Raffa stated. “This company is on the frontier of several important breakthroughs in medicine that could significantly improve the care of cardiology patients.”

Dr. Raffa holds Bachelor’s degrees in Chemical Engineering and Physiological Psychology from the University of Delaware, Master’s degrees in Biomedical Engineering (from Drexel University) and Toxicology (Thomas Jefferson University), and a doctorate in Pharmacology (Temple University School of Medicine). Dr. Raffa was a Research Fellow and Team Co-Leader for analgesics discovery at Johnson & Johnson and was pivotal in the elucidation of the mechanism of action and development of the analgesic tramadol

(Ultram™). He holds several patents, including the combination of tramadol plus acetaminophen (Ultracet™).

Dr. Raffa has published over 300 papers in peer-reviewed journals, is the co-author or editor of several books on pharmacology and thermodynamics, and is a Co-Editor of *Journal of Clinical Pharmacy and Therapeutics*. He is past president of the Mid-Atlantic Pharmacology Society and he is the recipient of research and teaching awards. He maintains an active research effort, has been funded by the NIH, and lectures and consults worldwide on analgesics.

“We at Native Cardiovascular are very pleased to welcome Bob Raffa to the Scientific Advisory Board ,”said Joseph Pergolizzi, MD, president and CEO of Native Cardiovascular Inc. “I have had the privilege of working with Bob on numerous projects and I recognize the tremendous expertise and insight he brings to any project. Bob shares my passion for solving complex medical problems, and his addition will bring great strength to the Native Cardiovascular organization.”

About Native Cardiovascular, Inc.

Native Cardiovascular, Inc. is a medical device/pharmaceutical development company committed to restoring quality of life to patients. As a company, we embrace the ever-changing healthcare environment by identifying current and future unmet needs. We then design and develop innovative medical products to address these unmet needs. Our goal is to utilize the latest technology to develop products that use a minimally invasive medical pathway to treat patients and that are cost efficient for both the patient and the healthcare delivery system. Our product, the NativeCVS Targeted Tissue Delivery System, addresses an unmet need in the treatment of atrial fibrillation.

For additional information please visit: www.nativeCVS.com.